Malassezia factor with antibiotic activity

Patent metadata

Field	Value
Publication number	US-2022380416-A1
Application number	US-202217827244-A
Country	US
Kind code	A1
Filing date	May 27, 2022
Priority date	May 28, 2021
Publication date	Dec 1, 2022
Grant date	—

Abstract

Compositions including an antibiotic factor from Malassezia are provided. In some examples, the compositions include a Malassezia exoproduct, a Malassezia cell-free supernatant, or a Malassezia cell and a pharmaceutically acceptable carrier. Methods of treating an infection in a subject, such as a Staphylococcus infection are also provided.

First claim

We claim:

1 . A composition comprising a Malassezia exoproduct, a Malassezia cell-free supernatant, or a Malassezia cell; and a pharmaceutically acceptable carrier.

2 . The composition of claim 1 , wherein the Malassezia is Malassezia sympodialis, Malassezia restricta , or Malassezia globosa.

3 . The composition of claim 1 , wherein the composition inhibits growth of Staphylococcus by at least 10-fold compared to a control.

4 . The composition of claim 3 , wherein the Staphylococcus is S. aureus , methicillin-resistant S. aureus , vancomycin-resistant S. aureus, S. caprae, S. epidermidis, S. haemolyticus , or S. warneri.

5 . The composition of claim 1 , wherein the Malassezia exoproduct exhibits one or more of heat resistance, binding to non-polar molecules, and pH sensitivity.

6 . The composition of claim 5 , wherein the pH sensitivity comprises antimicrobial activity at pH of about 6 or less.

7 . The composition of claim 1 , wherein the composition comprises about 0.01%-10% w/w, 0.01-10% v/v, or 0.01-10% w/v of the Malassezia exoproduct, cell free supernatant, or cells.

8 . The composition of claim 1 , further comprising an additional antibiotic compound.

9 . The composition of claim 1 , wherein the composition is formulated for topical administration.

10 . The composition of claim 8 , wherein the topical formulation comprises a solution, a gel, an ointment, a cream, or a suspension.

11 . The composition of claim 9 , wherein the pharmaceutically acceptable carrier is a base comprising a plurality of inactive ingredients.

12 . A method of inhibiting bacterial growth, infection, and/or skin colonization in a subject, comprising administering the composition of claim 1 to the subject.

13 . The method of claim 12 , wherein the bacteria is a Staphylococcus species.

14 . The method of claim 13 , wherein the Staphylococcus species is S. aureus , methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), or S. epidermidis.

15 . The method of claim 12 , wherein the composition is administered orally or intravenously.

16 . The method of claim 12 , wherein the composition is administered topically.

17 . The method of claim 12 , further comprising administering to the subject an additional antibiotic therapy.

18 . The method of claim 17 , wherein the additional antibiotic therapy is administered to the subject prior to, concurrently with, or following treatment with the composition.

Assignees

• Barber Matthew
• Kowalski Caitlin
• Univ Oregon

Inventors

• Barber Matthew
• Kowalski Caitlin

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P31/04 Primary

  Antibacterial agents · CPC title

• C07K14/37 Primary

  from fungi · CPC title

• C12P1/02

  by using fungi · CPC title

• C12N1/14

  Fungi (culture of mushrooms A01G18/00; as new plants A01H15/00); Culture media therefor · CPC title